MedTrace Logo

Cardiotoxicity Prevention in Breast Cancer Patients Treated With Anthracyclines and/or Trastuzumab

NCT02236806 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 262

Last updated 2022-02-01

No results posted yet for this study

Summary

The aim of the study is to analyze the protective impact on the cardiac damage of beta blockers and ACE inhibitors for breast cancer patients treated with anthracyclines-based chemotherapy with or without trastuzumab.

Conditions

Interventions

DRUG

Bisoprolol

5 mg daily

DRUG

Ramipril

5 mg daily

DRUG

Placebo

1 capsule daily

Sponsors & Collaborators

  • University of Florence

    collaborator OTHER

  • Azienda Ospedaliero-Universitaria Careggi

    lead OTHER

Principal Investigators

  • Lorenzo Livi, MD, Prof · Azienda Ospedaliero-Universitaria Careggi

  • Icro Meattini, MD, Prof · University of Florence

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2022-06-30
Completion
2022-06-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02236806 on ClinicalTrials.gov